[1825 days] Profiles of Drug Substances, Excipients and Related Methodology: Critical Compilation of pKa Values for Pharmaceutical Substances

[1825 days] Profiles of Drug Substances, Excipients and Related Methodology: Critical Compilation of pKa Values for Pharmaceutical Substances

0 đánh giá

CHI TIẾT SẢN PHẨM

Mã sản phẩm:

9780122608339

Tồn kho:

Còn hàng

Danh mục

Mua eTextbooks trực tuyến

Nhà xuất bản:

Elsevier S & T

Trạng thái:

Có hàng

Loại bìa:

Page Fidelity

Ngôn ngữ:

English

Tác giả:

Brittain, Harry G.

Special Price 6,350,000 VNĐ

Còn VNĐ nữa bạn sẽ được miễn phí giao hàngTìm hiểu thêm

Mua hàng số lượng lớn

Thời gian giao hàng Xem thêm

Chính sách đổi trả Xem thêm

Số lượng

Mô tả
Đánh giá (0)

Whilst following in the footsteps of previous volumes by presenting comprehensive reviews of drug substances and additional materials, this title also heralds a significant expansion of the scope of the series. Traditional contributions will now also be augmented by publication of critical review chapters that summarize information related to the characterization of drug substances and excipients. This change is required to better meet the needs of the pharmaceutical communtiy and to allow the development of a timely vehicle for publishing review materials on this topic.

The scope of the Profiles series will encompass review articles and database compilations that fall within one of the following six broad categories: Physical profiles of drug substances and excipients; Analytical profiles of drug substances and excipients; Drug metabolism and pharmacokinetic profiles of drug substances and excipients; Methodology related to the characterization of drug substances and excipients; Methods of chemical synthesis; and Reviews of the uses and applications for individual drug substances, classes of drug substances, or excipients.

* Presents comprehensive reviews covering all aspects of drug development and formulation of drugs
* Now encompassing critical review chapters
* Meets the information needs of the drug development community